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Abstract
One of the mechanisms by which adult disease can arise from a fetal origin is by in utero disruption
of organogenesis. These studies were designed to examine respiratory function changes in aging
rats following transient disruption of lung growth at 16 days gestation. Fetuses were treated in
utero with a replication deficient adenovirus containing the cystic fibrosis conductance
transmembrane regulator (CFTR) gene fragment cloned in the anti-sense direction. The in utero-
treated rats demonstrated abnormal lung function beginning as early as 30 days of age and the
pathology progressed as the animals aged. The pulmonary function abnormalities included
decreased static compliance as well as increased conducting airway resistance, tissue damping, and
elastance. Pressure volume (PV) curves demonstrated a slower early rise to volume and air
trapping at end-expiration. The alterations of pulmonary function correlated with lung structural
changes determined by morphometric analysis. These studies demonstrate how transient
disruption of lung organogensis by single gene interference can result in progressive change in lung
function and structure. They illustrate how an adult onset disease can arise from subtle changes in
gene expression during fetal development.
Background
The diseases that result from prematurity often occur
acutely in the perinatal period and are the result of an
undeveloped organ exposed to the extra uterine environ-
ment. However, as survival of the acute perinatal period
increases in these infants, observations have been made of
an increased incidence of late or adult onset diseases in
this population. These adult diseases include diabetes,
obesity, cardiovascular disease, and asthma [1-4] and
demonstrate how changes in the fetal environment can
have a profound effect on physiology into the adult.
Lung organogenesis is in part dependent upon stretch-
induced differentiation via contraction of the embryonic
airway smooth muscle [5-7]. One protein recently shown
by this laboratory to modify stretch induced lung organo-
genesis is the cystic fibrosis transmembrane conductance
regulator protein or CFTR [8]. Multiple independent lines
of evidence have suggested that CFTR is involved in lung
development (for reviews see [1,9]). Recently, this labora-
tory demonstrated that in utero CFTR expression levels
regulate Wnt/β-catenin signaling [10] through the parath-
yroid hormone related peptide (PTHrP) as demonstrated
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in the Troday-Rehan model for stretch-induced differenti-
ation of the lung [11-15].
This laboratory developed the technique of in utero gene
transfer into the pulmonary and intestinal epithelium
using low dose adenoviruses [16-19]. In subsequent
papers we and others have demonstrated that this method
completely bypasses the inflammatory response normally
seen in virus mediated gene transfer if performed with a
low dose and at the proper developmental stage in mice,
rats, and nonhuman primates [10,16,20-27]. In addition,
it was demonstrated previously with both C-MYC and
CFTR that gene function can be transiently inhibited by
the in utero infection of the lung and intestines with an
adenovirus carrying an antisense gene construct. This
process results in an approximate 50% reduction in gene
expression [10,24,25]. This method of transient in utero
knockout was subsequently validated independently by
traditional transgenic mouse technology when the role of
Wnt/Myc signaling in gut development was confirmed
[28].
The use of adenovirus transferred genes to the developing
epithelium, called transient in utero knockout (TIUKO),
was used previously with antisense CFTR and resulted in
altered lung structure, constitutive inflammation, and
increased airway reactivity in young adult rats [29]. These
results suggested that a transient change in expression of a
single gene during development could disrupt a develop-
mental cascade and permanently change lung structure
and function. Given the role of stretch induced differenti-
ation in lung growth and development with the participa-
tion of CFTR in stretch induced regulation of Wnt/β-
catenin signaling, transient alteration of CFTR can be
equated with transient modification of stretch.
In this study, the TIUKO CFTR method was again used to
interfere with stretch-induced lung organogenesis in the
fetal rat. Lung structure and function were examined to
determine if transient changes in a single fetal gene
involved in mechanicosensory differentiation could result
in progressive pathology in an aging lung.
Methods
In-utero gene transfer
An adenovirus carrying anti-sense CFTR (ASCFTR) gene
fragment was constructed as previously described[25]. In
utero gene transfer was performed at 16 days gestation
using a recombinant adenovirus carrying either the
ASCFTR or the control genes EGFP/LacZ. Both viruses
used a CMV promoter for transgene expression. Timed-
pregnant Sprague-Dawley rats were induced (5%) and
sedated (2%) with inhaled isoflurane. The uterine horns
were exposed by midline laparotomy and the individual
amniotic sacs were exposed and externalized. Each indi-
vidual amniotic sac was injected with a fine (27 gauge),
needle containing adenoviral particles in Dulbecco's Min-
imal Essential medium at 10% of the amniotic fluid vol-
ume. The average final concentration of adenovirus was
108 pfu/ml of amniotic fluid. Prior studies showed this to
be an efficient method of intrauterine gene transfer to the
pulmonary epithelium [17]. Control rats underwent an
identical surgical procedure but were injected with adeno-
virus carrying either EGFP or LacZ reporter genes. The
mothers were allowed to deliver normally and the rat
pups were raised under standard conditions in unfiltered
cages to more closely replicate normal environmental
exposures up to 18 months of age. The animals were ana-
lyzed serially at various time points up until 18 months of
age. Routine monitoring of health by the vivarium staff
did not reveal any evidence of chronic infections in either
control or treated animals.
Respiratory Function Testing
Animals undergoing pulmonary function testing were
anesthetized with intra-peritoneal pentobarbital at a dose
of 90 mg/kg. Anesthetic effect was monitored by tail
pinch. Animals then underwent tracheotomy with a
secured metal cannula and were connected to a flexiVent
(SCIREC, Montreal, Canada) computer-controlled small
animal ventilator. The animals were ventilated in a quasi-
sinusoidal fashion at a rate of 150 breaths/min with an I:E
ratio of 66.67%. Maximum peak inspiratory pressure was
set at 30 cm of water. Cylinder piston displacement was
set to provide a tidal volume of 10 ml/kg when gas com-
pression was taken into account. Positive end-expiratory
pressure (PEEP) was controlled by submerging the expira-
tory limb from the ventilator into a water trap. The ani-
mals were allowed five minutes to adjust to the ventilator
at a PEEP of 3 cmH2O and then were paralyzed with an
intraperitoneal injection of pancuronium bromide (0.5
mg/kg). Paralytics were required to completely inhibit any
respiratory activity that would interfere with respiratory
function testing. All animal protocols were approved by
the institutional animal care and use committee.
Respiratory mechanics
Automated respiratory function testing was performed
using the flexivent ventilator. After cessation of spontane-
ous respiration, PEEP was set to 0 cm water and the rat was
ventilated for 1 minute to equilibrate. Mechanical ventila-
tion was interrupted and the animal expired against the
set PEEP for 1 second. Dynamic PV curves were then deter-
mined. After renewed ventilation for 1 minute to re-equil-
ibrate, an 8 second broad-band petrubation signal
consisting of 18 equally spaced superimposed sine waves
with frequencies ranging from 0.25 Hz to 19.625 Hz was
applied to the lungs with the flexivent ventilator. Correc-
tion for mechanical characteristics of the ventilator circuit
was made using dynamic callibration data. This wasRespiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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obtained by applying volume pertubations through the
circuit both open and closed to the atmosphere prior to
connection of animals to the ventilator. The ventilator
was recalibrated between each animal. All measurements
were made in triplicate and were repeated at PEEP of 3
and 6 cm of water after 1 minute of ventilation at each
new PEEP to equilibrate.
Pulmonary impedance measurement was interpreted of
in terms of the constant phase model [30]. Airway resist-
ance (Raw) is a frequency independent Newtonian resist-
ance reflecting the conducting airways [31]; G
characterizes tissue damping; and H characterizes tissue
stiffness (elastance). We also calculated hysteresivity (eta
= G/H), which increases when regional heterogeneities
develop in the lung [32]. We corrected for lung size using
lung weight normalization for each animal. The forced
oscillation technique described above has been used by
other authors to perform respiratory function testing on
both animals and human patients [33].
Pressure-Volume Curves
Equal numbers of both treatment and control animals
were analyzed. Dynamic pressure-volume curves were
determined by inflating the lungs to a maximum pressure
of 30 cm H2) abd allowing passive exhalation using the
computer controlled Flexivent ventilator for measuring
volume and pressure. All measurements were performed
in triplicate. Individual results from each animal were
compiled. Averages and standard deviations for each level
of PEEP were determined. Two way ANOVA were per-
formed on the data and results were graphed. PV curves
were normalized by dividing volume by total lung com-
pacity and graphed in Graphpad Prism 5.
Histochemistry and Collagen Analysis
Masson's trichrome stain was performed (Sigma Chemi-
cal Co) on tissues fixed in methanol-free, 4% buffered
paraformaldehyde. A blinded investigator captured
images of trichrome stained lung tissue from 18 month
old animals at a final magnification of 40×. Collagen con-
tent was determined by pixel count using Adobe Pho-
toshop software [25,34].
Morphometry
Animals undergoing morphometric analysis did not
undergo respiratory function testing in order to preserve
tissue integrity. Tissues were coded and identified by a
number that each animal received at the time of sacrifice.
This number was used for identification of all histology
samples and served to blind the individuals performing
morphometric analysis. The trachea was cannulated and
the lungs were inflated at a constant pressure at 20 cm
H2O for 24 hours in methanol-free 4% buffered parafor-
maldehyde. Lungs that did not maintain constant infla-
tion were eliminated from the analysis. Sections from the
upper, middle and lower left lung were embedded sepa-
rately in paraffin for individual analysis [35].
Images from each entire section were captured at a final
magnification of × 25 for point-counting morphometry.
Volume densities of airway, parenchyma and vessels were
estimated using a lattice of 121 test points. Parenchyma
was defined as the gas-exchanging compartment that con-
tained the alveoli and ducts. Airways consisted of con-
ducting airways to the level of the terminal bronchioles.
In addition, 20 images of parenchyma from each section
were captured at × 400 final magnification. Volume den-
sities of airspace wall, airspace and inter-airspace wall dif-
ference were determined from these images. Inter-airspace
wall difference (mean linear intercept (Lm)) was deter-
mined by counting the number of intercepts of a line of
known length.
Two blinded investigators (in addition to the individual
who captured the images) performed morphometry using
the identification numbers with treatment groups uniden-
tified.
Statistical Analysis
Respiratory function testing and airway reactivity were
analyzed using both paired t-test and ANOVA (GraphPad
software). Following morphometric analysis, the upper,
middle, and lower lobes were analyzed separately. No sig-
nificant differences were attributed to specific lobes; there-
fore, morphometric data from lungs were pooled within
each treatment group and age. Tissue volume proportion
and collagen content were compared between the control
and experimental groups using two-tailed t-test (Graph-
Pad software). A p < 0.05 was considered statistically sig-
nificant. All values are presented as mean ± standard error
of mean.
Results
Adult airway histopatholgy following transient in utero 
gene intereference
Previous studies performed in this laboratory demon-
strated an increase in collagen surrounding the airways at
100 days of age following in utero gene transfer of
ASCFTR [25]. To determine the affects of aging on these
airway changes, animals were examined at 18 months of
age following fetal treatment. Fetuses treated at 16 days
gestation with recombinant adenovirus carrying the
ASCFTR were compared to control animals that had
received AdCMVlacZ at the same gestation. These animals
were examined after they were raised under standard con-
ditions in unfiltered cages following normal delivery. The
level of CFTR inhibition of coharts of the animals used in
this study was documented and previously publishedRespiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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[25]. CFTR expression was found to be reduced by approx-
imately 50%.
Trichrome staining was performed on lung sections from
both control and TIUKO CFTR animals at 18 months of
age. Previous work in this lab demonstrated fibrosis in
TIUKO CFTR animals at 100 days of age[25]. As shown in
Figure 1, increased fibrosis was observed (demonstrated
by blue stain) in animals in which lung organogenesis
had been transiently disrupted with ASCFTR (panel B) as
compared to the reporter gene, control, treated animals
(panel A). Thus, the fibrosis observed previously at 100
days of age persisted into late adulthood. Photomicro-
graphic quantitation via pixel counts of images (Figure 1,
panel C) showed that a highly significant (p < 0.0001)
increase in collagen content in the treated rat lungs as
compared to the control group. There was no significant
difference in the control pixel counts between 100 days
(8) and 18 months demonstrating no fibrosis due to ade-
novirus vector. The collagen content in the ASCFTR
treated lungs at 18 months was approximately 4-fold
increase over controls as compared to a 1.7-fold increase
over controls in the 100 day old animals [25]. Thus, the
fibrotic lung histopathology in adult rats following
TIUKO CFTR appeared to be progressive.
Altered pulmonary mechanics in TIUKO CFTR rats at 18 
months of age
Previous studies demonstrated altered airway reactivity
and inflammatory changes in TIUKO CFTR animals as
young adults [29]. These changes were shown to be unre-
lated to the gene therapy procedure as they were not
observed in any of the previous publications by this and
other laboratories using the in utero gene theapy method
[10,16,20-27]. Given the airway histopathology observed
at 18 months of age (Figure 1), one would expect persist-
antly altered respiratory mechanics in the lungs of the ani-
mals as they aged.
Respiratory function tests were performed on 18 month
old adult animals following ASCFTR treatment at 16 days
gestation. A significant decrease in static compliance (Cst)
was noted in the TIUKO rats; these results were consistent
across all levels of PEEP (Figure 2, panel A). The decrease
in static compliance was consistent with the increase in
collagen content noted in the conducting airways of the
TIUKO rats at the same age (Figure 1, panel B).
The constant-phase model analysis demonstrated a signif-
icant increase in conducting airway resistance (Raw) at all
levels of PEEP (Figure 2, Panel B). In addition, there was a
signficant increase in tissue damping (Figure 2, Panel C)
which reflected altered tissue resistance. The independ-
ently determined constant phase model elastance (H) was
significantly increased in the treatment group at all levels
Trichrome staining demonstrating increased collagen at 18  months of age following in-utero gene transfer Figure 1
Trichrome staining demonstrating increased colla-
gen at 18 months of age following in-utero gene 
transfer. (A) Airway of an 18 month old animal following 
injection at 16 days gestation with AdCMVlacZ (control). (B) 
Airway of an 18-month-old animal following injection at 16 
days gestation with ASCFTR. (C) Pixel analysis of collagen 
content. *p < 0.0001.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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Respiratory function at 18 months of age following in utero gene transfer at 16 days gestation Figure 2
Respiratory function at 18 months of age following in utero gene transfer at 16 days gestation. Respiratory func-
tion in 18 month old animals following treatment at 16 days gestation with replication deficient adenovirus containing eGFP, 
(control, solid bars), or anti-sense CFTR gene fragment, (ASCFTR, crossed bars). (A) static compliance. (B), conducting airway 
resistance, (Raw). (C) tissue damping. (D) elastance. (E) hysteresivity, (eta). Four animals are included in each data point. All 
data were obtained in triplicate for each animal. Error bars are ± standard error of mean. * p < 0.005; ** p < 0.004; # p < 0.02.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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of PEEP, (Figure 2, panel D). Hysteresivity, (eta), was
decreased at PEEP of 0 and 3 cm water but was not signif-
icantly increased at PEEP of 6, (Figure 2, Panel E).
Pressure-volume (PV) curves demonstrated the require-
ment for higher pressures to inflate the lungs in treated
rats during the early phase of the respiratory cycle (Figure
3). In addition, air trapping was noted as the PV loop did
not return to baseline volume at the end of exhalation.
Increased variability during the expiratory phase of the
respiratory cycle was noted as was hyperinflation.
Decreased airway density in TIUKO CFTR rats at 18 
months of age
In addition to the increased collagen in the airways of the
TIUKO CFTR animals at 18 months of age (Figure 1), the
volume proportion of airways in the lungs was decreased
in the TIUKO CFTR animals as compared to the controls
(Figure 4, Panel A). The decreased airway density in the
lungs of these animals may have also contributed to the
increased conducting airway resistance that their pulmo-
nary function testing demonstrated. In contrast, the vol-
Changes in PV curves at 18 months of age following in-utero gene transfer at 16 days gestation Figure 3
Changes in PV curves at 18 months of age following in-utero gene transfer at 16 days gestation. Respiratory func-
tion in 18 month old animals following treatment at 16 days gestation with replication deficient adenovirus containing eGFP, 
(control, solid lines), or anti-sense CFTR gene fragment, (ASCFTR, dashed lines). Four animals are included in each data point. 
PV curves were obtained in triplicate for each animal. All data is presented as mean ± SEM. p < 0.0001.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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Morphometric analysis of lung structure with age following in utero gene transfer at 16 days gestation Figure 4
Morphometric analysis of lung structure with age following in utero gene transfer at 16 days gestation. Amniotic 
sacs were injected at 16 days gestation with replication deficient adenovirus containing either EGPF, (Control, solid lines), or 
anti-sense CFTR gene fragment, (Antisense, dashed lines). Morphometric analysis was performed on animals at 2, 4, 7, and 18 
months of age. Volume proportions of airways (A), blood vessels (B), and parenchyma (C) are presented as mean ± SEM. *p < 
0.05.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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ume proportion of blood vessels was increased at this age
in the ASCFTR treated animals (Figure 4, Panel B).
Alterations in parenchyma in TIUKO CFTR rats during 
adolescence
Static compliance, (Cst), was significantly decreased in
adolescent animals as compared to their age-matched
controls while Raw was unchanged during the same time
period. In addition, elastance was signifcantly increased in
TIUKO CFTR animals as compared to controls at 17 days
of age and tissue damping was significantly increased in
the ASCFTR group at 17 days of age. These changes sug-
gested differences in parenchyma.
The parenchyma was examined closely at 400× final mag-
nification with point counting. While the volume propor-
tion of airways, vessels and parenchyma were unchanged
in the adolescent animals, quantitative evaluation of the
parenchyma demonstrated marked differences in these
young animals (Table 1). When the parenchyma was spe-
cifically examined, there was an increase in volume den-
sity of airspace wall and a decrease in volume density of
airspace. The complexity of the lung, suggested by Lm,
was decreased. While these changes were highly signifi-
cant in the adolescent animals, significance was lost while
the animals aged.
Alterations in lung structural changes in TIUKO CFTR rats 
as a function of age
To determine if pulmonary structural alterations and tis-
sue remodeling reflected the altered pulmonary mechan-
ics, morphometric analysis was performed on the lungs of
the animals as they aged. As with the pulmonary mechan-
ics, the young ASCFTR adults enjoyed periods of relative
structural normality and morphometric analysis of young
adults did not show any differences in the volume densi-
ties of the airways, parenchyma or vessels. However, alter-
ations occurred as the animals aged (Figure 4).
In the control animals, the volume proportion of paren-
chyma was highest in young adulthood. With age the den-
sity of airways and vessels increased and the volume
proportion of parenchyma decreased (Figure 4, solid
lines).
During their adolescence, both the control and TIUKO
CFTR animals showed wide variance in their volume den-
sities. During that time the ASCFTR adolescent lung struc-
ture did not vary significantly from their aged-matched
controls. After 60 days of age there was an increase in the
volume proportion of airways in young adult animals
treated with ASCFTR as compared to control animals (Fig-
ure 4, panel A); these differences remained through 90–
120 days of age and corresponded to a significant decrease
in the volume proportion of parenchyma at the same age
(Figure 4, panel C). This differed markedly from the statis-
Table 1: Effect of in utero ASCFTR on lung parenchyma.
Age
(days)
Group % Parenchyma %
Airspace
A/P Lm
13 Control (eGFP) 0.18956612 0.712707 3.787066 18.8125
13 ASCFTR 0.24464738 0.673135 2.806436 20.99217
p = .003 p = .03 p = .004 p = .012
60 Control (eGFP) 0.12055785 0.773347 6.508026 19.15
60 ASCFTR 0.12007576 0.778168 6.862095 20.2
NS NS NS NS
90 Control (eGFP) 0.19871534 0.790174 4.622078 21.62444
90 ASCFTR 0.21126822 0.765983 4.568619 19.96945
NS NS NS NS
120 Control (eGFP) 0.16403409 0.850143 5.70228 18.405
120 ASCFTR 0.16472577 0.880894 5.84488 18.14
NS NS NS NS
210 Control (eGFP) 0.14146006 0.802755 6.003154 18.54375
210 ASCFTR 0.1651343 0.771823 4.979818 18.59688
NS NS NS NS
Detailed morphometric examination of the parenchyma at each age was performed by point counting at × 400 final magnification. Twenty images 
were examined from upper, middle and lower sections of each left lung following fixed-inflation. Volume densities of airspace wall, airspace and 
inter-airspace wall difference were determined by point counting. Inter-airspace wall difference (mean linear intercept (Lm)) was determined by 
counting the number of intercepts of a line of known length.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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tically signifcant decrease in the airway density of the old
adults treated in utero with ASCFTR. At 210 days of age
the the volume proportion in the airways and parencyma
did not vary significantly from the conrol group. After 210
days of the control group increased its airway density
while the ASCFTR group did not. This resulted in a signfi-
cant decrease in airway density as compared to controls at
18 months of age (Figure 4, Panel A). These data are futher
evidence of progressive disease throughout adulthood
despite the transient nature of the ASCFTR treatment.
The volume proportion of blood vessels was consistently
increased throughout adulthood in the TIUKO CFTR ani-
mals, however this difference only reached significance at
18 months of age (Figure 4, Panel B).
Altered pulmonary mechanics in TIUKO CFTR rats as a 
function of age
Respiratory function was examined in the ASCFTR ani-
mals at various timepoints up to 18 months of age (17,
30, 90, 120, and 540 days of age). Changes of respiratory
mechanics over time are presented in Figure 5.
Static complinace, (Cst), was significantly decreased in
adolescent ASCFTR treated animals as compared to their
age-matched controls (Figure 5, Panel A). However, these
values normalized as the animals reached young adult-
hood and at 90–120 days of age the static compliance in
the TIUKO CFTR animals did not vary significantly from
the control animals. However, as the animals aged, the
TIUKO CFTR adults demonstrated significant decreases in
their static compliance as compared to their control coun-
terparts.
In contrast, conducting airway resistance, (Raw), was ini-
tially normal in the young TIUKO CFTR animals as com-
pared to their age-matched controls. The large differences
in airway resistance appeared only as the animals became
aged into late adulthood (Figure 5, Panel B).
Elastance, (H), demonstrated the same bimodal pattern as
Cst. At 30 days of age elastance was signifcantly increased
in TIUKO CFTR animals as compared to controls. These
values normalized and there was loss of significance dur-
ing young adulthood (90–120 days) with a return to a sig-
nificant increase by 18 months of age (Figure 5, Panel C).
A decrease in elastance is a marker of normal lung devel-
opment in the adolescent and it is known to decrease
steadily until 17 days of age in the Sprague-Dawley rat
[36]. The elevation of elastance through 30 days of age
was consistent with a delay in maturation in the TIUKO
CFTR animals. Although the young adults were able to
exhibit near normal functions during young adulthood
(similar to Cst and Raw), this parameter also began to
deteriorate as the animals aged.
Tissue damping, (G), was significantly increased in the
ASCFTR group at 30 days of age. By 90 days of age there
was loss of significance (Figure 5, Panel D). Hyteresivity,
(eta), showed marked variability as the animals aged (Fig-
ure 5, Panel E). By 18 months of age it was significantly
decreased at PEEP of 0 and 3 cm H2O.
Discussion
During normal development the fetus is exposed to
numerous transient insults that can affect organogenesis.
Using standard methods for manipulating gene expres-
sion such as transgenic mice with and without inducible
promoters it is impossible to depress gene expression in a
small number of cells and then have that gene recover due
to normal cell turnover or expansion. The transient in
utero gene transfer system used in this study is the only
method affecting a specific gene. In addition, the stoichi-
ometry of this method results in disruption of only a very
small number of cells. A total of <107 infectious units are
delivered to the entire fetus. Given the distribution of
virus to the lung, intestines, skin, and amnion [16,17,27]
less than 106 cells are transfected with the transgene in the
lung.
Until the recognition of the role of CFTR in stretch-
induced regulation of muscle contractions and Wnt/β-cat-
enin signaling [8,10] it was difficult to understand how
affecting such a small number of cells could have signifi-
cant effects on lung structure and function. Because the
process of stretch-induced differentiation is a global proc-
ess, small changes would be amplified by altered expres-
sion of genes such as CFTR or Rho kinase[37].
Transient in utero knockout of CFTR resulted in a pattern
of evolving respiratory function and structure with age.
During their adolescence the animals treated in utero with
ASCFTR demonstrated mechanical and histologic evi-
dence of parenchymal immaturity. In young adulthood
the animals enjoyed a period of relative health followed
by progressive disease culminating in significant mechan-
ical and histologic disease at 18 months of age. That these
results were specific to the transient inhibition of CFTR in
utero can be seen with the normal lungs in control ani-
mals treated with adenovirus reporter, thus it is not due to
in utero adenovirus-specific lung response. In addition,
previous studies with adenovirus mediated over expres-
sion of CFTR in which lung growth and development was
actually stimulated and enhanced pulmonary functions
observed [20,21,26]
Adolescent animals following in utero treatment with
ASCFTR showed signficant alterations in respiratory func-
tion compared to their aged-matched controls. Specifi-
cally, tissue damping and elastance were elevated at 30
days, while compliance was decreased. In addition, mor-Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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Respiratory function with age following in-utero gene transfer at 16 days gestation Figure 5
Respiratory function with age following in-utero gene transfer at 16 days gestation. Respiratory function testing at 
17, 30, 90, 120 days and 18 months, (PEEP 3 shown) following in utero treatment with an adenovirus containing either EGFP, 
(control, solid lines), or anti-sense CFTR gene fragment, (ASCFTR, dashed lines). (A) static compliance (Cst). (B) conducting 
airway resistance, (Raw). (C) elastance (D) tissue damping. (E) hysteresivity, (eta). All data were obtained in triplicate. Eight ani-
mals are included in each data point. Error bars are ± standard error of mean. Results at PEEP of 0 and 6 were similar, (data 
not shown). *p < 0.05.Respiratory Research 2009, 10:34 http://respiratory-research.com/content/10/1/34
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phometric analysis of the parenchyma at this age demon-
strated an increase in volume density of the airspace wall,
a decrease in volume density of airspace and decreased
complexity. These findings deviate from the normal devel-
opmental pattern of respiratory function as described by
Broussard et al. In the Sprague-Dawley rat tissue damping
and elastance declines through 17 days of age until reach-
ing an equilibrium. This coincides with alveolarization
and thinning of the interstitium [36]. The delay in the
normal decline in tissue damping and elastance in the
TIUKO CFTR animals is consistent with a delay in lung
development. This theory is supported by other work in
this laboratory demonstrating a CFTR-dependant cascade
that affects cytoskeletal tension during lung organogene-
sis [1,8].
The TIUKO CFTR animals enjoyed a period of normal pul-
monary mechanics in young adulthood (90–120 days of
age). In contrast, the volume density of their airways was
increased by morphometric analysis at the same age. This
is not dissimilar to findings in young children with CF.
Recently, high-resolution computed tomography imaging
has demonstrated that infants with CF have more dilated
airways with thicker walls in the absence of abnormal pul-
monary function [38]. At 210 days of age the volume pro-
portion of the airways and parencyma did not vary
significantly from the conrol group.; had morphometric
analysis been done only at that time point no differences
would have been noted.
Late adulthood following in utero ASCFTR treated was
associated with a progressive decline in respiratory func-
tion. By 18 months of age there were signficant differences
in both the structure and function of the lungs of the
ASCFTR animals as compared to their aged-matched con-
trols. The lungs demonstrated decreased Cst and increased
H. Conducting airway resistance was increased at this
time. Increased tissue damping suggested changes in the
parenchymal tissue and the decrease in hysteresivity
reflected inhomogeneity of the lungs. The loss of signifi-
cance in eta at higher levels of PEEP suggested that this
inhomogeneity is due to both focal fibrosis as well as sur-
factant system dysfunction.
The PV curves in the animals at 18 months of age demon-
strated several abnormalities. Greater pressure required to
inflate the lungs as well as air trapping at end expiration
were noted. In addition, a large amount of variability was
noted on the exhalation phase of the respiratory cycle.
This is the passive phase on the ventialtor, completely
dependent on lung properties. The variability is due to the
different responses of each animal to environmental con-
ditions and represents the inhomogenity of the disease
process. Adult patients with cystic fibrosis often demon-
strate air trapping on pulmonary function testing similar
to that found in our ASCFTR group [39-43]. They also
demonstrate hyperinflation and decreased compliance as
was demonstrated in our ASCFTR animals [40-44]. Our
results are consistant with these characteristics of lung
function found in the adult cystic fibrosis patients popu-
lation.
In addition, there were structural changes in the lungs by
18 months of age in the TIUKO CFTR group. The older
animals demonstrated a decrease in volume density of air-
ways and an increase in volume density of blood vessels.
There was an increase in collagen content in these lungs.
These findings are consistent with a pattern of tissue
destruction and remodeling.
Chronic inflammation in the lungs is a hallmark of cystic
fibrosis. It is still debated wether this early chronic inflam-
matory state exists as a primary component of cystic fibro-
sis or if persistent infection causes this inflammation.
Regardless of the cause, this chronic inflammation leads
to obstructive lung disease and tissue destruction. This
results in bronchiectasis and respiratory failure over time.
While inflammation was not addressed in this paper, pre-
vious work in this laboratory demonstrated a constitutive
pro-inflammatory state in the TIUKO CFTR treated ani-
mals [29]. A pro-inflammatory state in CFTR deficiency
has been demonstrated by others [45-49].
This work demonstrates that transeint disruption of
stretch-induced organogenesis can result in progress lung
disease due to disruption of organogenesis. Interestingly,
some aspects of CF pathology may originate in fetal life
from the total absence of CFTR. As migh be expected CF
pathology would be much greater than that observed in
this transient model.
The fetal origin of adult disease has been recognized and
debated for nearly two decades with growing evidence in
support [50-56]. Recent work in this laboratory describes
cystic fibrosis as a "Peter Pan Disease" where the lung is
immature at birth and never "grows up" [1]. This immatu-
rity leads to the progressive disease process observed in
our animal model and possibly has some contribution to
humans with CF. There is a critical period in fetal develop-
ment where CFTR expression is required for normal lung
development. Alteration of CFTR expression during this
time period results in an immature lung by alteration of
stretch-induced organogenesis. It also results in an altered
inflammatory state with a shift toward chronic low-grade
inflammation. Despite recovery of normal CFTR expres-
sion subsequent to this critical developmental period the
lung never recovers.
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